NCT01590446View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Achondroplasia
Interventions
DRUG

BMN 111

SC injection, Part 1 single dose and Part 2 multiple dose.

DRUG

Normal Saline

SC injection, Part 1 single dose and Part 2 multiple dose

Trial Locations (1)

47710

Covance CRU Inc., Evansville

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY